Characiejus Dainius, Pasukoniene Vita, Jonusauskaite Renata, Azlauskaite Nijolek, Aleknavicius Eduardas, Mauricas Mykolas, Otter Willem Den
Institute of Oncology, Vilnius University, Vilnius, Lithuania.
Anticancer Res. 2008 Mar-Apr;28(2B):1139-42.
The objective of this study was to evaluate the significance of CD8highCD57+ lymphocytes for the survival of high risk melanoma patients treated with adjuvant interferon-alpha (IFN-alpha).
The prognostic significance of peripheral blood CD8highCD57+ lymphocyte levels for survival was analysed retrospectively in 16 IFN-alpha-treated melanoma patients with resected regional lymph node metastases. The survival of the patients was analyzed using the Kaplan-Meier method. The difference between survival curves was determined using the log-rank test.
The median survival time of patients with >23% CD8highCD57+ lymphocytes prior to treatment with IFN-alpha was 14.2 months, whereas the median survival time of patients with < 23% CD8highCD57+ lymphocytes was not reached at the time of analysis (median follow-up 24.6 months).
Larger prospective studies are justified to investigate the precise value of CD8highCD57+ lymphocytes in the selection of melanoma patients for adjuvant treatment with IFN-alpha.
本研究的目的是评估CD8高表达CD57+淋巴细胞对于接受辅助性α-干扰素（IFN-α）治疗的高危黑色素瘤患者生存的意义。
回顾性分析16例接受IFN-α治疗且有区域淋巴结转移切除史的黑色素瘤患者外周血CD8高表达CD57+淋巴细胞水平对生存的预后意义。采用Kaplan-Meier法分析患者的生存情况。使用对数秩检验确定生存曲线之间的差异。
在接受IFN-α治疗前CD8高表达CD57+淋巴细胞>23%的患者，其中位生存时间为14.2个月，而CD8高表达CD57+淋巴细胞<23%的患者在分析时未达到中位生存时间（中位随访24.6个月）。
有必要开展更大规模的前瞻性研究，以探究CD8高表达CD57+淋巴细胞在选择接受IFN-α辅助治疗的黑色素瘤患者中的精确价值。
